Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer

Clinica Chimica Acta

Volumn 371, Issue 1-2, 2006, Pages 92-96

  Liu, Shu Chih ^a   Yang, Shun Fa ^a   Yeh, Kun Tu ^b   Yeh, Chung Min ^b   Chiou, Hui Ling ^a   Lee, Ching Yi ^a   Chou, Ming Chih ^a   Hsieh, Yih Shou ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Matrix metalloproteinase 2; Tumor size

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; ZYMOGRAPHY;

BREAST NEOPLASMS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GELATIN; HUMANS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM STAGING; REGRESSION ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33746718055     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.02.026     Document Type: Article

References (37)

1. Klahr S., Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89 (2003) 1270-1275
2. Garbett E.A., Reed M.W., Stephenson T.J., and Brown N.J. Proteolysis in human breast cancer. Mol Pathol 53 (2000) 99-106
3. Yoon S.O., Park S.J., Yun C.H., and Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36 (2003) 128-137
4. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13 (1999) 781-792
5. Curran S., and Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189 (1999) 300-308
6. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
7. Duffy M.J., Maguire T.M., Hill A., McDermott E., and Higgins O.'N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2 (2000) 252-257
8. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135-1149
9. Leppa S., Saarto T., Vehmanen L., Blomqvist C., and Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10 (2004) 1057-1063
10. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., and Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58 (1998) 1395-1399
11. Sheen-Chen S.M., Chen H.S., Eng H.L., Sheen C.C., and Chen W.J. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 173 (2001) 79-82
12. Azzam H.S., Arand G., Lippman M.E., and Thompson E.W. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85 (1993) 1758-1764
13. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., and Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90 (2004) 1414-1421
14. Hanemaaijer R., Verheijen J.H., Maguire T.M., et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 86 (2000) 204-207
15. Duffy M.J., and McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 12 (1998) 1343-1348
16. Duffy M.J. Proteases as prognostic markers in cancer. Clin Cancer Res 2 (1996) 613-618
17. Giannelli G., Erriquez R., Fransvea E., et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 109 (2004) 782-785
18. Hirvonen R., Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 77 (2003) 85-91
19. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325-329
20. Yang S.F., Chu S.C., Chiang I.C., et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 352 (2005) 209-215
21. Yang S.F., Hsieh Y.S., Lin C.L., et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 354 (2005) 91-99
22. Rha S.Y., Yang W.I., Kim J.H., et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5 (1998) 875-879
23. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9 (2005) 267-285
24. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., and Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14 (1994-95) 246-258
25. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83 (1998) 1153-1162
26. Kossakowska A.E., Huchcroft S.A., Urbanski S.J., and Edwards D.R. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73 (1996) 1401-1408
27. Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89 (2003) 1270-1275
28. Chang H.R., Yang S.F., Li M.L., Lin C.C., Hsieh Y.S., and Lian J.D. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366 (2006) 243-248
29. Fisher B., Redmond C., Poisson R., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320 (1989) 822-828
30. Fisher B., Anderson S., Fisher E.R., et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338 (1991) 327-331
31. Veronesi U., Marubini E., Del Vecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87 (1995) 19-27
32. Shek L.L., and Godolphin W. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48 (1988) 5565-5569
33. Ferno M., Baldetorp B., Bendahl P.O., et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen-especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 36 (1995) 23-34
34. Kurizaki T., Toi M., and Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 5 (1998) 673-677
35. Lebeau A., Muller-Aufdemkamp C., Allmacher C., et al. Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth. J Mol Histol 35 (2004) 443-455
36. Glasspool R.M., and Twelves C.J. Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast 10 (2001) 368-378
37. Maquoi E., Sounni N.E., Devy L., et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6- trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 10 (2004) 4038-4047